Q-omics provides the consensus-scored RPS27 profile across patient tissues and cancer cell-line models. RPS27 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPS27 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, RPS27 protein abundance shows 26,926 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, KIRC, and PDAC as cancer lineages where RPS27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS27 survival associations across molecular data types. RPS27 RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS27 RNA expression–survival associations across cancer types. High RPS27 expression shows unfavorable associations in KIRP, SCLC, ACC and LIHC, but favorable associations in BRCA and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RPS27 RNA expression.
This table summarizes RPS27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RPS27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS27 shows lower tumor expression in KICH, UCEC and LUSC and higher tumor expression in KIRC, LIHC and CHOL. The KIRC box plot shows higher RPS27 RNA expression in tumor versus normal tissue (log2 FC = +0.828, t-test p < 0.001).
This table shows molecular features associated with RPS27 in patient tissues and cancer cell lines. In patient samples, RPS27 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS27 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
